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Abstract
Cervical cancer remains among the most common cancers in women worldwide and 
can be prevented by vaccination. The Ministry of Health, Labour and Welfare of Japan 
suspended active recommendation of regular human papillomavirus (HPV) vaccines 
in 2013 because of various symptoms including chronic pain and motor impairment. 
This nationwide case-control study from April 2013 to March 2017 targeted women 
aged 20-24 years old at cervical screening. We compared HPV vaccination exposure 
between those with abnormal and normal cytology. Abnormal cytology was classi-
fied based on the results of histological test and we calculated the odds ratio (OR) 
and 95% confidence interval (CI) of the above endpoints and vaccination exposure 
using the conditional logistic regression model and estimated vaccine effectiveness 
using the formula (1 – OR) × 100. A total of 2483 cases and 12 296 controls (one-
to-five matching) were eligible in 31 municipalities in Japan. The distribution of his-
tological abnormalities among cases was 797 CIN1 (including dysplasia) (32.1%), 165 
CIN2 (6.7%), 44 CIN3 (1.8%), and eight squamous cell carcinoma (SCC) (0.3%). The 
OR of HPV vaccination compared with no vaccination for abnormal cytology, CIN1+, 
CIN2+, and CIN3+ versus controls was 0.42 (95% CI, 0.34-0.50), 0.42 (95% CI, 0.31-
0.58), 0.25 (95% CI, 0.12-0.54), and 0.19 (95% CI, 0.03-1.15), respectively, equating 
to a vaccine effectiveness of 58.5%, 57.9%, 74.8%, and 80.9%, respectively. Eight 
patients had SCC, none was vaccinated. This nationwide case-control study in Japan 
demonstrated a substantial risk reduction in abnormal cytology and CIN among 
women who did versus those who did not receive HPV vaccination.
K E Y W O R D S
case-control study, cervical intraepithelial neoplasia, HPV vaccine, human papillomavirus, 
vaccine effectiveness
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1  | INTRODUC TION
Cervical cancer remains one of the most common cancers in women 
worldwide, and infection with high-risk types of human papillomavi-
rus (hrHPV) is a cause of precancerous cervical lesions and cervical 
cancer.1 To date, the 2vHPV (HPV type 16/18), 4vHPV (HPV type 
6/11/16/18), and nonvalent (HPV type 6/11/16/18/31/33/45/52/58) 
vaccines have been globally approved, and large observational cohorts 
and randomized trials demonstrated their acceptable safety profiles 
and high efficacy against hrHPV infections as well as precancers.2-8
In Japan, there were a total of 10 490 new cases in 2014 and 2795 
women died of cervical cancer in 2017.9 The age-standardized inci-
dence of cervical cancer has been increasing since 2000, especially 
in women aged <40 years.10 Even at the precancerous intraepithelial 
stage, frequent biopsies can be burdensome, and conization for CIN3 
can also affect the risk of preterm birth during subsequent pregnan-
cies. The 2vHPV vaccine was launched in October 2009, followed by 
the 4vHPV vaccine in August 2011. Subsidies from local and national 
governments for a three-dose HPV vaccination program for girls aged 
13-16 years old started in November 2010. However, due to the occur-
rence of various symptoms including chronic pain, motor impairment, 
and others, the Ministry of Health, Labour and Welfare (MHLW) of 
Japan announced the suspension of the proactive recommendation for 
routine use of the HPV vaccine in the national immunization program 
on June 2013, just two months after its inception.11 As a result, the 
HPV vaccination rate among younger women has decreased sharply 
from a peak of about 70% in 2013 to the current rate of <1% for those 
born after 2002.12 As for this circumstance in Japan, the World Health 
Organization’s Global Advisory Committee on Vaccine Safety com-
mented that young women have been left vulnerable to preventable 
HPV-related cancers.13
To date, the effectiveness of HPV vaccination for Japanese 
women has not been sufficiently investigated. There are no na-
tionwide databases for vaccination and cancer screening registries 
as well as frameworks for evaluating vaccine efficacy. In addition, 
because most studies conducted in Japan used a self-reported vac-
cination history,14 vaccine effectiveness has not been correctly esti-
mated due to misclassification of self-reported vaccination history.14 
We, a designated research group of the MHLW of Japan, conducted 
a nationwide case-control study of HPV vaccine efficacy using cy-
tology results, histology results, and vaccination history from official 
records in various municipalities. This study aimed to estimate the 
effect of the HPV vaccine against abnormal cytology and cervical 
intraepithelial neoplasia (CIN)1+, CIN2+, and CIN3+ in Japanese 
women.
2  | MATERIAL S AND METHODS
2.1 | Study overview
In Japan, cervical cancer screening has been provided in residential 
areas, workplaces, and individual health check-ups. Cytology using 
conventional methods and liquid sample methods has been widely 
used as a cervical cancer screening method. The resident screening 
is conducted and managed mainly by each municipality (city, town or 
village). The screening target population was women aged ≥ 20 years 
old since April 2004 and municipalities maintain individual records of 
screening histories. Similarly, individual cervical cancer vaccination 
records are also managed by each municipality.
In the present study, case-control analysis was carried out using 
data on cervical cancer screening and HPV vaccination history ob-
tained from 31 municipalities. We announced study participation 
to all 80 municipalities, centering on the prefectural capital in each 
prefecture; of them, 31 agreed to participate. Figure 1 shows the 
study subjects and study framework. The girls shown in the dotted 
areas were the age group widely vaccinated under public subsidies 
by an HPV vaccination program started for girls aged 13-16 years 
in 2010-2013 who would have a high percentage of cervical cancer 
vaccine inoculation. In contrast, those in the diagonally lined areas 
were the age group at the time of vaccination cessation as a result 
of suspension of the governmental recommendation in 2013, so it is 
assumed that the vaccination rate would be low. The study period 
was set from April 1, 2013 to March 31, 2017 and the target popu-
lation was women aged 20-24 years at the time of cervical screen-
ing. As a result, women born between 1994 and 1997 shown in the 
dot-framed areas (aged 20-23 years in 2014-2017) had a chance to 
get immunized, whereas those born between 1990 and 1993 in the 
thick-framed areas (aged 20-24 years in 2013-2017) did not. We 
compared proportions of HPV vaccinated between abnormal cytol-
ogy and normal cytology groups to analyze the association between 
HPV vaccination and cervical precancerous lesions.
2.2 | Case-control definitions
The participant enrolment process is shown in Figure 2. Individual 
data of cervical cancer screenings of women aged 20-24 years from 
the fiscal years of 2013-2017 were obtained from 31 municipalities 
across Japan. According to the Community Health Business Report, 
the total number of cervical cancer screening examinees among 
women with our target age in these research municipalities was a 
total of 93 937 women during the study period (15 455 in fiscal year 
2013, 25 356 in fiscal year 2014, 19 946 in fiscal year 2015, 16 685 
in fiscal year 2016, and 16 495 in fiscal year 2017, respectively).15The 
case-controls status was determined from the cervical cancer 
screening results. The results were coded according to Bethesda 
coding.16 Patients with abnormal cytology (atypical squamous cells 
of undetermined significance [ASC-US]+ of Bethesda) were selected 
as “cases,” while “controls” were selected from those with normal 
cytology (negative for intraepithelial lesion or malignancy [NILM] of 
Bethesda). Five controls matched with the exact birth year and clos-
est examination date were selected for each case in each municipal-
ity. As a result, 2817 cases and 13 988 controls were available.
This study excluded women with any of the following character-
istics: history of abnormal cytology, unknown Bethesda, and history 
     |  3IKEDA Et Al.
of moving into a municipality since November 2010, and unclear 
HPV vaccination history. In addition, the controls whose matched 
cases met the exclusion criteria were also excluded. As a result, a 
total of 2483 cases and 12 296 controls were finally eligible for this 
analysis. Among 1014 cases of those with histological abnormalities, 
132 cases were described as dysplasia only (without definite classi-
fication of CIN) and classified as CIN1 in this study. As the exact age 
and date of birth were not provided to the research group because 
of protection rules for personal information in some municipalities 
(305 cases, 2200 controls), in our analysis, these cases and controls 
were categorized as “the non-specific age group”.
2.3 | Vaccination record survey
Because Japan has no national vaccine registry, each municipality 
manages its own official immunization records. Therefore, informa-
tion about individual vaccination status including the date of inocu-
lation, lot number, and number of doses was linked with the data 
of the cervical cancer screening by the public health center of each 
municipality. In this study, researchers received anonymous linked 
datasets from each municipality and integrated them for our analy-
sis. As the vaccination history in other municipalities could not be 
collected, subjects with a history of moving in from other municipali-
ties were excluded from our analyses.
2.4 | Statistical analysis
Data are shown as mean ± standard deviation for continuous values 
and their percentages for categorical values by age or fiscal year for 
the eligible women. A conditional logistic regression model was used 
to calculate the odds ratio (OR) for preventing cytology/histology 
abnormalities. Abnormalities were classified into abnormal cytology, 
CIN1+, CIN2+, and CIN3+, and we estimated the OR due to vac-
cination exposure for each status. As for women having dysplasia 
without grading CIN, we classified it as CIN1+ in this analysis, be-
cause they had at least CIN1. We also estimated vaccine effective-
ness using the formula (1 – OR) × 100. As a sensitivity analysis, OR 
and its effectiveness were calculated excluding two municipalities 
in which most pathological results were missing, All P values were 
two-sided and those <0.05 were considered statistically significant. 
F I G U R E  1   Research subjects and research framework. Girls shown in the dotted areas (aged 13-16 years in 2010-2012) were in the 
widely vaccinated group, whereas those in the diagonally lined areas (aged 16 years in 2013) were in the vaccination cessation group. 
As a result, women born between 1994 and 1997 shown in the dot-framed areas (aged 20-23 years in 2014-2017) had the chance to get 
immunized, whereas those born between 1990 and 1993 in the thick-framed areas (aged 20-24 years in 2013-2017) did not
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All statistical analyses were carried out using STATA version 14.0 SE 
software (Stata Corp LP).
2.5 | Ethical issues
This study was approved by the Ethics Review Board at Osaka 
University Graduate School of Medicine (approval number 15248-7). 
The requirement for individual informed consent was waived.
3  | RESULTS
Table 1 presents the number of cytology/histology results by age. 
There were 2483 cases of abnormal cytology. The age distribution 
between cases and controls was similar. In terms of histological re-
sults, there were 797 cases (32.1%) of CIN1 (including dysplasia), 165 
cases (6.7%) of CIN2, 44 cases (1.8%) of CIN3, and eight cases (0.3%) 
of squamous cell carcinoma. The proportion of patients who did not 
undergo a histological examination did not differ by age, and the pro-
portion of CIN1 (including dysplasia) and CIN2 also did not change 
among age. However, the number of CIN3 cases tended to increase 
with age (from 0.9% in women aged 20 years to 2.0% in those aged 
24 years).
The proportion of HPV vaccinated are compared between cases 
and controls in Table 2. A total of 404 of 2483 (16.3%) cases received 
the vaccination versus 2605 of 12 296 (21.2%) controls. Among 
women aged 20-23 years, the vaccination rate was higher in the con-
trols than in the cases. The detailed pattern of controls who received 
vaccines by fiscal year and birth fiscal year is noted in Table 3. The 
generation born after 1994 is the group when the subsidies for HPV 
vaccination started, and the vaccination rate in that age group was 
52.9%. The vaccination rate of the unspecified age group was 16.1% 
in cases and 16.5% in controls.
The effectiveness of HPV vaccine against histological abnor-
mality for eligible Japanese women is shown in Table 4. The OR for 
abnormal cytology was 0.42 (95% CI, 0.34-0.50), equating a vaccine 
effectiveness of 58.5%. The OR in CIN1+ was 0.42 (95% CI, 0.31-
0.58) and in CIN2+ was 0.25 (95% CI, 0.12-0.54), equating to a vac-
cine effectiveness of 57.9% and 74.8%, respectively. In addition, the 
OR in CIN3+ was 0.19 (95% CI, 0.03-1.15) and vaccine effectiveness 
was 80.9%. In this study, there were five patients with squamous 
cell carcinoma and three patients with invasive cancer, but none was 
vaccinated.
In a sensitivity analysis excluding data from two municipalities 
in which most pathological results were missing, the results were 
almost the same (Table S1).
4  | DISCUSSION
In this case-control study, the association between HPV vaccine 
inoculation and cervical precancerous lesions was examined by 
cervical cancer screening between 2013 and 2017. We estimated 
that the HPV vaccine provided a 58.5% reduction against cyto-
logical abnormality, 57.9% protection for CIN1+, and 74.8% for 
CIN2+. As for CIN3+, the vaccination tended to show an 80.9% 
reduction, although it was not statistically significant. Importantly, 
no cases of invasive cancer were observed among the HPV vac-
cinated women.
F I G U R E  2   Patient enrollment process
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Misclassification between self-reported status and official HPV 
vaccination records in Japan was reported by Yamaguchi et al.14 In 
their paper, 14.8% (140/949) of participants having confirmed vac-
cination in the official vaccination record remembered incorrectly 
that they had not been vaccinated. In contrast, 40.2% (113/281) of 
participants not having confirmed vaccination in the official record 
remembered that they had been vaccinated. They argued that pos-
sible reasons for this discrepancy were: (i) incorrect recognition of 
other vaccines, such as influenza or Japanese encephalitis; (ii) vac-
cination in a different municipality due to changing address; and (iii) 
vaccination not using official subsidies, such as catch-up vaccination. 
It seems that reason (i) accounted for the most cases, although pos-
sibilities for reasons (ii) and (iii) may remain.
Some reports have shown the protective effectiveness of 
HPV vaccines against HPV infections and intraepithelial lesions in 
Japan.17-26 Except for the study by Kudo and colleagues, they are 
based on the memory of vaccination history. Kudo and colleagues 
estimated the vaccine efficacy of HPV 16/18 infection prevention. 
They did not evaluate abnormalities in cytology and histology, and 
their outcomes were different from ours. Furthermore, they used 
municipal vaccination records, but the target population was the 
residents who lived in only six cities in Niigata Prefecture; Niigata, 
Nagaoka, Joetsu, Shibata, Mitsuke, and Sanjo cities.17 Matsumoto 
and colleagues analyzed the reduction of HPV 16/18 prevalence in 
intraepithelial lesions by the HPV vaccine based on a self-report. 
This was not a study that directly verified the efficacy of HPV vac-
cine to prevent precancerous lesions. Because there were no data 
of participants without abnormal cytology, its vaccine effectiveness 
could not be estimated. In addition, it was not a population-based 
study because they collected data from 21 medical institutions.19 
Ozawa and colleagues reported that vaccinated women showed 
a significant decrease in CIN1+ of 64.9% and CIN2+ of 85.5% in 
a limited area, Miyagi prefecture, with a small sample size of 5924 
women.25 Konno and colleagues used data from 16 branches out 
of 46 branches in 47 prefectures, and evaluated the efficacy of the 
vaccine based on personal memory of vaccination history among the 
subjects.26 The proportion of people in their late twenties, who were 
mostly unvaccinated, is high (64%). As a result, only four cases of 
HSIL+ with vaccination were reported in the study by Konno and 
colleagues, which was considerably less than the 25 cases with 
CIN2+ with vaccination in our study.
Furthermore, in a systematic review and meta-analysis re-
porting the effect at 5-9 years after HPV vaccination, CIN2+ de-
creased significantly by 51% (relative risk, 0.49; 95% CI, 0.42-0.58) 
among screened girls aged 15-19 years and decreased significantly 
by 31% (relative risk, 0.69; 95% CI, 0.57-0.84) among women aged 
20-24 years. In our study, a 74.8% efficacy was observed for CIN2+. 
One possible reason for the less efficacy of HPV vaccine in sys-
tematic review than this study is that a systematic review included 
the single-cohort vaccination and low routine vaccination cov-
erage country.8 Another possible reason is that the prevalence of 
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One of the main strengths of this large-scale study is that ad-
ministrative databases of 31 municipalities, 23 prefectures out of 47 
prefectures from Hokkaido to Kagoshima, covering approximately 
11% of the population enabled us to conduct comprehensive evalu-
ation of the effect of HPV vaccination at the national level. In addi-
tion, immunization status was confirmed by municipal records, not 
Age
Cases Controls
Number Vaccinated Number Vaccinated
20 343 115 (33.5%) 1633 703 (43.0%)
21 581 172 (29.6%) 2710 1119 (41.3%)
22 369 36 (9.8%) 1629 261 (16.0%)
23 533 29 (5.4%) 2330 148 (6.4%)
24 352 3 (0.9%) 1794 11 (0.6%)
Unspecified age 305 49 (16.1%) 2200 363 (16.5%)
Total 2483 404 (16.3%) 12 296 2605 (21.2%)
Abbreviation: HPV, human papillomavirus.
TA B L E  2   Comparison of HPV 
vaccination rates between cases and 
controls by age at screening
TA B L E  3   Attained age, number of NILM and HPV vaccination positives in controls according to birth year and screening year
Screening year
2013 2014 2015 2016 2017
Birthyear
1990 23y/o, 78 (0) 24y/o, 564 (0)
1991 22y/o, 157 (0) 23y/o, 909 (17) 24y/o, 445 (11)
1992 21y/o, 314 (0) 22y/o, 406 (2) 23y/o, 541 (11) 24y/o, 314 (0)
1993 20y/o, 265 (0) 21y/o, 651 (1) 22y/o, 421 (0) 23y/o, 421 (9) 24y/o, 462 (0)
1994 20y/o, 403 (42) 21y/o, 550 (284) 22y/o, 391 (83) 23y/o, 381 (111)
1995 20y/o, 273 (175) 21y/o, 550 (313) 22y/o, 254 (176)
1996 20y/o, 343 (200) 21y/o, 645 (521)
1997 20y/o, 349 (286)
Abbreviations: HPV, human papillomavirus; NILM, negative for intraepithelial lesion or malignancy.
Number of HPV vaccination positives in parentheses. Birth year and screening year are counted as fiscal year.
TA B L E  4   HPV vaccination status and effectiveness
Cases (with histological result)
Negative CIN1 CIN2 CIN3 SCC/invasive
Vaccination (+) 70 136 22 3 0
Vaccination (‒) 273 661 143 41 8
Controls Cases
Cumulative number of cases (with histological result)
CIN1+ CIN2+ CIN3+
Vaccination (+) 2605 404 161 25 3
Vaccination (‒) 9691 2079 853 192 49




0.34-0.50 0.31-0.58 0.12-0.54 0.03-1.15
Vaccine 
effectiveness
58.5% 57.9% 74.8% 80.9%
Abbreviation: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
CIN1+ = CIN1(including dysplasia) + CIN2 + CIN3 + SCC/invasive. CIN2+ = CIN2 + CIN3 + SCC/invasive. CIN3+ = CIN3 + SCC/invasive.
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by individual memory to avoid misclassification of vaccination his-
tory. As mentioned before, according to the report by Yamaguchi 
et al, the memory difference was confirmed quite often regarding 
the presence or absence of vaccination.14 To ensure that the immu-
nization status was correct, we excluded participants with a history 
of moving into a municipality after the initiation of HPV vaccination 
program in November 2010 in the records of the municipalities. 
Moreover, as we aimed to evaluate the efficacy of the HPV vac-
cine focusing on the cases with newly diagnosed CIN, we excluded 
women with a history of abnormal cytology. These efforts lead to 
a more accurate assessment of HPV vaccine effectiveness. In this 
study, we evaluated cervical intraepithelial lesions, rather than veri-
fying the efficacy of HPV vaccines to prevent HPV infection.
As described above, although the efficacy of HPV vaccine is 
reported worldwide, in some cases, various symptoms after vacci-
nation have also been reported. Thus, for the safety of HPV vaccina-
tion, analyses have been carefully performed of various symptoms 
reported after vaccination such as chronic pain, movement disorders, 
and orthostatic dysregulation.28 In Japan, a national epidemiological 
study was also conducted to evaluate the safety of HPV vaccination 
by the other MHLW research group. In December 2016, the safety 
results were reported. In this report, even girls who did not receive 
the HPV vaccination showed various non-specific symptoms similar 
to those reported in inoculated girls.29
This study has some limitations, however. First, as sexual behav-
ior was not included in the survey items, if women vaccinated after 
their sexual debut were included in this study, the vaccine might be 
less effective, whereas if they were excluded, vaccine effectiveness 
might be overestimated. Second, regarding the histological results, 
there was only a description of dysplasia and in some municipalities 
the specific diagnosis was unknown. However, we obtained similar 
results despite excluding data from two municipalities without de-
tailed histological results. Third, we could not find data on how many 
women had vaccinated as catch-up vaccination in Japan. Although it 
is an extreme assumption, if a 40% false-positive rate in the report 
by Yamaguchi and colleagues is used as the proportion of catch-up 
vaccinations and applied to those who have not been vaccinated in 
this study, the odds ratio was estimated to be 0.88 (0.82, 0.97), which 
indicates the effectiveness of the vaccination with statistical signif-
icance. Therefore, the effectiveness of the HPV vaccine was shown 
even when the catch-up vaccination was taken into consideration.
Notably, in a modelling study in 2019, the prediction of cervical 
cancer age-adjusted morbidity reached an estimated 2099 at the 
end of the 21st century according to predictions using the current 
HPV vaccination and cervical cancer screening rates. Globally, the 
higher the national development index, the lower the prevalence.30 
According to the modelling study, Japan is in the group with the 
highest national development index, but the predicted value of cer-
vical cancer incidence is positioned as the highest in that group.30 
In Japan, cervical cancer, especially refractory adenocarcinoma, 
has been increasing in young women.10 Therefore, we believe 
that our findings showing the effectiveness of HPV vaccination in 
Japan are very important data when considering the resumption of 
recommendations by the MHLW of Japan and increasing the vacci-
nation rate thereafter.
In conclusion, this nationwide case-control study in Japan 
demonstrated a risk reduction of 58% for CIN1+ and 75% for CIN2+ 
among women with versus those without HPV vaccination. In Japan, 
the HPV vaccination rate is approaching zero, and cervical cancer 
has been increasing among younger women. To avoid tragedy that 
can be prevented by HPV vaccination, our findings suggest that 
resurgence of the proactive recommendation of MHLW for nation-
wide HPV vaccinations is needed in Japan.
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